Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...